Vertex Pharmaceuticals Incorporated

VRTX21 Jan 2025
Healthcare
$428.32
+0.01 (+0.77%)
Lowest Today
$423.49
Highest Today
$428.75
Today’s Open
$428.32
Prev. Close
$422
52 Week High
$519.88
52 Week Low
$377.85
To Invest in Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

Healthcare
VRTX21 Jan 2025
+0.01 (+0.77%)
1M
3M
6M
1Y
5Y
Low
$423.49
Day’s Range
High
$428.75
423.49
52 Week Low
$377.85
52-Week Range
52 Week High
$519.88
377.85
1 Day
-
1 Week
+2.05%
1 month return
+6.45%
3 month return
-11.69%
6 month return
-14.16%
1 Year return
-2.97%
3 Years return
+82.83%
5 Years return
+80.4%
10 Years return
-
Institutional Holdings
Capital World Investors
10.41
Vanguard Group Inc
8.99
BlackRock Inc
8.46
State Street Corp
4.59
FMR Inc
4.09
Capital Research Global Investors
3.5
Vanguard Total Stock Mkt Idx Inv
3.15

Market Status

Fundamentals
Market Cap
108677.23 mln
PB Ratio
6.95
PE Ratio
0
Enterprise Value
103855.76 mln
Total Assets
22730.2 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older;  ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial;  VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Organisation
Vertex Pharmaceuticals Incorporated
Employees
5400
Industry
Biotechnology
CEO
Dr. Reshma  Kewalramani FASN, M.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities